Neuroscience

Neurohacker Announces Name Change To Qualia Life Sciences As Part Of ExpansionNeurohacker Announces Name Change To Qualia Life Sciences As Part Of Expansion

Neurohacker Announces Name Change To Qualia Life Sciences As Part Of Expansion

CARLSBAD, Calif., Sept. 18, 2024 /PRNewswire/ -- The pioneering health and wellness brand formerly known as Neurohacker Collective, has recently completed…

10 months ago
Flourish Research Announces Strategic Majority Investment from Genstar CapitalFlourish Research Announces Strategic Majority Investment from Genstar Capital

Flourish Research Announces Strategic Majority Investment from Genstar Capital

Investment to bolster leading multi-site clinical trial organization to further scale across therapeutic areas and geographies APEX, N.C. and SAN…

10 months ago
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by AnhedoniaEngrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers…

10 months ago
14th Annual Nikon Small World in Motion Competition Winner Captures Embryonic Development in Fruit Flies14th Annual Nikon Small World in Motion Competition Winner Captures Embryonic Development in Fruit Flies

14th Annual Nikon Small World in Motion Competition Winner Captures Embryonic Development in Fruit Flies

Detailing the intricate process of early embryogenesis, this year's winning video provides insights into fundamental biological processes with far-reaching implications.…

11 months ago
Anervea Welcomes Jack Capponi as Chief Commercial Officer and Board Member, Driving Global Expansion with AI-Powered SolutionsAnervea Welcomes Jack Capponi as Chief Commercial Officer and Board Member, Driving Global Expansion with AI-Powered Solutions

Anervea Welcomes Jack Capponi as Chief Commercial Officer and Board Member, Driving Global Expansion with AI-Powered Solutions

ORLANDO, Fla., Sept. 16, 2024 /PRNewswire/ -- Anervea.ai, a global leader in AI-powered commercialization solutions for the Pharmaceutical, Life Sciences,…

11 months ago
Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer’s TestingDarmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer’s Testing

Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer’s Testing

SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ -- Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch…

11 months ago
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysisIpsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints…

11 months ago
KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care SolutionsKFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is cementing its…

11 months ago
Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravisJohnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis

Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis

Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and…

11 months ago